Brain tumors represent the most common solid tumors in childhood, accounting for almost 25% of all childhood cancer, second only to leukemia. Pediatric central nervous system tumors encompass a wide variety of diagnoses, from benign to malignant. Any brain tumor can be associated with significant morbidity, even when low grade, and mortality from pediatric central nervous system tumors is disproportionately high compared to other childhood malignancies. Management of children with central nervous system tumors requires knowledge of the unique aspects of care associated with this particular patient population, beyond general oncology care. Pediatric brain tumor patients have unique needs during treatment, as cancer survivors, and at end of life. A multidisciplinary team approach, including advanced practice nurses with a specialty in neuro-oncology, allows for better supportive care. Knowledge of the unique aspects of care for children with brain tumors, and the appropriate interventions required, allows for improved quality of life.
Central nervous system tumors are the second most common pediatric malignancy, second only to acute lymphoblastic leukemia, and represent the most common solid tumors in childhood. Overall, central nervous system tumors account for 22% of all pediatric cancer diagnoses ( Figure 1 ). Within the spectrum of central nervous system tumors there is a myriad of diagnoses ( Figure 2 ), ranging from benign to malignant, from low to high grade. While certain diagnoses, such as diffuse intrinsic pontine glioma, are known to have dismal survival rates, even a low grade astrocytoma with an excellent prognosis can have significant morbidity with potential to dramatically affect quality of life. Depending on the histiologic diagnosis, the plans for oncologic treatment, survivorship, and end-of-life care vary widely.
Throughout the spectrum of care these patients may have a combination of neurologic deficits including speech and swallowing impairments affecting communication and nutrition, vision changes, motor and sensory deficits, and impairments in balance and coordination. Headaches, fatigue, seizures, stroke, endocrinopathies, and neurocognitive and behavioral changes can develop at diagnosis, after surgery, after treatment, or at end of life. These deficits can improve and even resolve, but for the majority of patients they are chronic or evolving issues that impair function and require referrals to specialists in rehabilitative medicine, neuro-ophthalmology, neurology, endocrinology, psychiatry, and neuropsychiatry. With appropriate interventions and management pediatric patients with central nervous system tumors can have improved quality of life during treatment, survivorship, and at end of life.
Treatment ND is a 10-year-old boy with a 2-month history of slowly increasing fatigue, headaches and diplopia. Three days prior to presenting to the local emergency room he had 2 episodes of jerking of all extremities and uncontrollable laughter. He then developed lethargy, severe headache, and vomiting, and presented acutely to his local emergency room. Brain magnetic resonance imaging (MRI) confirmed a large midline mass occupying the pineal region and third ventricle, with resulting hydrocephalus. ND was transferred to the Pediatric Intensive Care Unit and started on dexamethasone and levetiracetam. Elevated serum alpha fetoprotein confirmed the diagnosis of a malignant central nervous system germ cell tumor. A ventriculoperitoneal shunt was placed. Spine MRI was negative and a lumbar puncture could not be performed due to extent of hydrocephalus. An endocrine work-up was negative. Residual deficits included mild somnolence, diplopia, Parinaud's syndrome, and nystagmus. Standard chemotherapy for central nervous system germ cell tumor was started emergently. Postchemotherapy MRI revealed residual disease and he underwent second look surgery, which confirmed residual tumor was mature teratoma. ND proceeded to radiation therapy, consisting of whole ventricle radiation with a boost to the tumor bed. He was referred to neuro-ophthalmology for vision deficits and to physical therapy for general weakness. He received home instruction and an individualized educational plan was developed to allow continued tutoring during treatment. Following completion of treatment he successfully transitioned back to school full time and was active in sports with accommodations for residual vision impairments.
Pediatric brain tumors encompass a wide range of pathologic classification. It is imperative to understand the pathology of the tumor because it directly impacts the child's extent of disease evaluation, treatment and prognosis. The World Health Organization (WHO) classification system for pediatric central nervous system neoplasms is used to specify the histology and grade of tumors. With increased understanding of the molecular signatures of many central nervous system tumors, the WHO classification will be updated in the future to include this information, which may be helpful in predicting prognosis, and possibly suggest new, targeted therapies. Staging of tumors is based on location and by dissemination within and beyond the central nervous system. 1 This information guides the team as they begin to care for the newly diagnosed child or adolescent and their family. Helping families and, in an age-appropriate approach, the child or adolescent, understand the significance of the pathology is an important first step in their treatment.
Clinical Presentation
The diagnosis of a central nervous system neoplasm starts with a detailed history elicited by the practitioner. Practitioners must be sensitive to the parents' anxiety as the questions are asked, particularly if the child has been unwell for a few weeks or months. A meticulous physical and neurological examination is performed. In general, a child who presents with rapidly progressing symptoms in a short time period is likely to have a rapidly growing malignant brain tumor, often associated with surrounding edema. The size and the location of the tumor contribute to the presenting symptomatology. Symptoms occur because of acute or chronic increased intracranial pressure and/or the infiltration or compression of surrounding areas of the central nervous system. Nonlocalizing symptoms that occur because of intracranial pressure can include headache, vomiting, changes in personality, diplopia from cranial nerve 6 (abducens) palsy, and papilledema and, in young children, rapidly increasing head circumference. Headaches that are new or have changed in nature from previous headaches, wake the child from sleep, occur upon awakening and worsen with the Valsalva maneuver are considered red flags. 2 Headaches accompanied by nausea or vomiting, particularly if vomiting relieves the pain, are particularly concerning. Localizing symptoms occur because of the tumor's location although there can be some overlap of symptoms. As an example, tumors in the cerebral hemispheres can cause headache, personality changes, memory loss, seizures, focal, motor or sensory deficits, hearing and visual field changes. Midline and suprasellar tumors can present with endocrinopathies, visual impairment and increased intracranial pressure. Cerebellar lesions causing hydrocephalus can also present with signs and symptoms of raised intracranial pressure but may also result in ataxia, cranial neuropathies, hemiparesis, and dysdiadochokinesis (Table 1) . 3, 4 Children with certain genetic syndromes or family history such as NF-1, NF-2, tuberous sclerosis, Li-Fraumeni syndrome, Gardner syndrome, Turcot syndrome, and Gorlin syndrome have a predisposition for developing central nervous system tumors and must be monitored appropriately. 5 
Diagnostic Evaluation
If the neurological exam reveals deficits, neuro-imaging, preferably an MRI with and without gadolinium, is performed. Visual and auditory aides such as music and movies are now available during MRI, and may help children tolerate a lengthy MRI. If a child is medically unstable or too young or anxious to lie quietly for an MRI, a computed tomography (CT) scan of the brain, ideally with and without iodinated contrast, can be done. Neuroradiologists may also recommend other imaging techniques tools such as diffusion-tensor imaging, dynamic contrast enhanced imaging, functional MRI, spectroscopy and a fluorodeoxyglucose positron emission tomography to further help characterize the lesion. 6, 7 The authors' institution is using a MRI hydrocephalus protocol which includes single shot fast spin echo imaging, axial diffusion weighted imaging and axial apparent diffusion coefficient imaging and, sometimes, susceptibility weighted imaging. The images are clear, scan time is short and there is no risk of radiation exposure. This scan, however, may not be practical for the very young, anxious or medically unstable child so the authors continue to use noncontrast CT scans to assess for hydrocephalus with these patients. Further work-up is dictated by the pathology of the primary tumor and may include lumbar puncture, bone marrow aspirate and biopsy, and bone scan. In primary central nervous system germ cell tumors, serum and cerebrospinal fluid alpha fetoprotein and human chorionic gonadotropin levels can be diagnostic. 8 Knowing the full extent of disease at diagnosis is vital for treatment planning and prognosis.
Surgery
Neurosurgical intervention is the initial treatment modality for the majority of pediatric brain tumors, depending on location of the lesion, clinical status of the patient and disease dissemination. The goals for surgical intervention include obtaining a tissue diagnosis, removing or debulking the tumor, 9 and restoring normal cerebrospinal fluid flow via ventriculoperitoneal shunt or endoscopic third ventriculostomy. Intraoperative MRI may assist in achieving complete resection while decreasing morbidity by guiding the neurosurgeon away from vital structures/tracts. Endoscopic third ventriculostomy may prevent the placement of shunt hardware, decreasing the possibility of infection and the remote chance for extracranial disease spread. 9 In general, complete resections improve survival rates. However, the risk of morbidity in some cases is too high to consider surgery a safe option. With a diffuse intrinsic pontine glioma, for example, diagnosis has traditionally been based on clinical presentations and MRI findings; with the advent of molecular profiling and safer neurosurgical techniques, diffuse intrinsic pontine glioma is being more frequently biopsied. Molecular profiling may suggest a targeted therapy if standard therapeutic options fail. With hypothalamic chiasmatic gliomas, primary surgical resection is not recommended because of the risk of visual impairment. 10 Emergency neurosurgical interventions may be necessary with obstructive hydrocephalus, hemorrhage, or mass effect. Early diagnosis and treatment of increased intracranial pressure with the goal of optimizing cerebral perfusion and maintaining cerebral metabolic demands is critical to preventing brain injury. 11 Neurosurgical procedures carry intraoperative and postoperative risks. Complications can include infection, blood loss, neurological morbidity, hematoma, and edema. Cerebellar mutism or posterior fossa syndrome can occur 24-48 hours postoperatively after posterior fossa surgery. While there is a range of the severity of this syndrome, the child can develop mutism, hypotonia, emotional lability, and neurocognitive impairment. 12 There is no treatment protocol and recovery varies. Zolpidem has been used successfully to increase wakefulness, accelerate the resolution of the mutism and improve the irritability. 13 Rehabilitative services are critical and should be initiated as soon as the child is medically stable. Prior to discharge, patient and caretakers receive extensive personalized teaching from the practitioner so that they can recognize neurological deterioration and seek immediate medical attention. In addition, if indicated, the practitioner reviews the management of seizures and anticonvulsants and of diabetes insipidus and intranasal vasopressin. Steroid tapering is documented on a home diary and the families are aware of the possibility of hypertension, hyperglycemia, oral candidiasis, and dramatic mood swings.
Radiation Therapy
Radiation therapy is a vital component of the multimodal plan for the management of most malignant brain tumors in children over the age of 5 years. The pathology, location of the tumor, degree of surgical resection, disease dissemination and age of the child will determine the amount and type of radiation. Most centers use photon energy delivered either to a focal area or to the entire craniospinal axis. 14 Proton therapy, the most recent advancement in radiation therapy, delivers the same total dose but it can reduce the dose that may affect healthy tissue because of less scatter. 15 It has the potential to safely escalate higher doses to the high risk tumors. Proton beam radiation therapy may offer similar cure rates with fewer side effects but more head to head studies need to be published. 16 In most cases, radiation therapy is given daily for approximately 6 weeks, which allows the child/adolescent to tolerate a large cumulative dose. Delivering radiation therapy to a young or anxious child is more complicated because it involves daily anesthesia, although it is safely done in many centers. Immediate side effects of radiation therapy can include nausea, anorexia, and headache, which can be effectively addressed with medication. Skin changes in the field of radiation can result in reddened and irritated patches that respond to water base emollients and heal slowly after the therapy is completed. The plethora of longterm deficits that may be caused by radiation therapy alone or in combination with chemotherapy have been extensively documented. The goal of using conformal radiation therapy techniques to deliver precise doses to the tumor site(s) while sparing healthy tissue and structures will ideally lessen both acute and long-term radiation induced toxicities. Radiation therapy can also be used in a palliative setting and is a helpful tool that, in 1 study, resulted in a 58% overall response rate for neurological symptoms with no palliative patient experiencing significant toxicity. The symptoms improved with a median response time of about a week. 17 
Chemotherapy
The use of chemotherapy is guided by the tumor's pathology, extent of disease and age of the child. Challenges in adequately treating central nervous system tumors include penetrating the blood brain barrier and drug resistance. 14 Chemotherapy can be used prior to surgery, in combination with radiation therapy, as adjuvant therapy and to treat recurrent disease. It can be given daily or weekly during radiation therapy as a radiation sensitizer in certain tumors. High dose multi agent protocols, in combination with autologous stem cell rescue, in the very young (in most cases, less than age 3) are utilized to delay the use of radiation therapy until the brain is more developed. Lower doses of chemotherapy agents can be given for longer periods of time to treat low-grade gliomas that are not resectable. 18 Certain tumors such as medulloblastoma respond with improved survival rates to multimodal therapy. 19 Single agent chemotherapy such as temozolomide is usually given concurrently with radiation therapy for high grade gliomas and then used as adjuvant therapy. Although adjuvant therapy has slightly improved survival for high grade gliomas, the overall prognosis remains dismal. 20 Chemotherapy has proven not to be effective in the treatment of diffuse pontine gliomas and rarely is used in the treatment of ependymomas.
Clinical Trials
Although traditional cytotoxic chemotherapy has been used for decades, research in the treatment of central nervous system tumors is now focused on the development of biological agent and therapies targeted to intratumoral mutations. 14 Understanding the biology of various tumors including the important molecules and pathways responsible for the oncogenesis of tumors is crucial for the development of new agents. 21 New biologic agents are currently being studied in phase 1 and 2 clinical trials and potentially have better central nervous system penetration and fewer toxicities than conventional chemotherapy. 22, 23 Ongoing studies are crucial to the understanding of the toxicities and efficacy of these new agents when used alone or in combination with other agents or treatment modalities. It is critical that practitioners help families understand the importance of enrolling in a clinical trial. In this way, clinicians increase enrollment, share information about the small number of these patients, and advance the knowledge and use of these new agents. The family and the child (age appropriate) must be educated about compliance, possible side effects, and their management, and when the child needs to be seen emergently.
Multidisciplinary Interventions
Children with central nervous system tumors have a high likelihood of experiencing a variety of disabilities related to their tumor and the effects of the aforementioned treatment modalities. Rehabilitative services such as occupation and physical therapy are needed by many children for weakness ranging from a hemiplegia of the arm and leg to a subtle change in fine motor skills. Occupational and speech therapists can assist the child who has swallowing and speech difficulties to recover full function. The variety of possible ophthalmologic deficits must be carefully monitored. A child with diplopia may benefit from alternating eye patching so as to minimize the discomfort, while a child with visual loss will need special accommodations to help him orient to his environment. Neuro-ophthalmologists may recommend prism glasses for Parinaud's syndrome. Early recognition and treatment of endocrinopathies such as diabetes insipidus or syndrome of inappropriate antidiuretic hormone secretion will prevent further neurological complications. Neurocognitive baseline testing will help detect and address early neurotoxic effects such as memory deficits. Continued education is important to the child and the parent to maintain normalcy during treatment, and can be accommodated using 504 plans or individualized education plans. The social worker and psychologists help the child and family to work though the emotional and social issues that arise from having a brain tumor. 24 Treating a child with a primary central nervous system lesion requires a multidisciplinary approach and involves family members. Teaching and support are ongoing as the team and family relationship develops. The ideal goal of treatment is to eradicate the disease while sparing healthy tissue and structures. Early interventions are vital to help each child to reach their highest potential and live a fulfilling, happy life.
Survivorship
MF is an 8-year-old girl diagnosed at age 5 with standard risk medulloblastoma. Neuroimaging studies demonstrated a midline fourth ventricular mass without evidence of metastatic disease (see Figure 3 ). She underwent a gross total resection of the tumor and on postoperative day 2 developed posterior fossa syndrome. She received induction therapy with external beam radiation therapy consisting of 2340 cGy craniospinal radiation with a boost to the tumor bed of 3240 cGy for a total dose of 5580 cGy to the tumor bed, along with concurrent weekly vincristine. Estimated dose to the hypothalamic pituitary axis was 2800 cGy. Maintenance chemotherapy consisted of cisplatin, lomustine, and vincristine. One year after completion of treatment the patient was given an individualized survivorship care plan, including a treatment summary and comprehensive plan outlining the recommended follow-up for potential late effects (see Table 2 ). MF has residual complications including dysarthria, high frequency hearing loss, hemiparesis, ataxia, neurocognitive dysfunction, and fine and gross motor deficits. She developed growth hormone deficiency and hypothyroidism, which are managed by an endocrinologist. Formal neuropsychological testing revealed decreased processing speed as evidenced by learning difficulty. Arrangements were made for appropriate supportive services and educational accommodations at school, including speech, occupational, and physical therapies. She made steady strides with continued rehabilitation. Ongoing issues with debilitating low self-esteem and anxiety related to diagnosis and late effects persist for which she sees a psychologist.
Advancements in treatment modalities have dramatically improved survival rates for children who have been diagnosed with a brain tumor. The 5-year relative survival rate following diagnosis of a primary malignant brain tumor for children between 0-19 years of age is 73%. 25 Long-term survivorship has prompted many new treatment regimens aimed at reducing late effects while maintaining the survival rates. The authors have learned that ''less is more'': fewer radical surgical procedures, lower doses of radiation therapy, smaller volumes of radiation therapy, and fewer and less intensive courses of chemotherapy. 26 Unfortunately, many childhood brain tumor survivors are still at significant risk for adverse long-term health-related complications, referred to as late effects. Most of these late effects can be attributed to direct neurologic damage to the developing brain caused by the tumor itself, surgery, the long-term toxicity of chemotherapy, or the effects of irradiation on the central nervous system. In general, children who are treated at a young age and those who receive the most intensive therapy (ie, high doses of radiation combined with high doses of chemotherapy) are more likely to develop late effects. Late effects may develop months to years after completion of cancer treatment. 27 In addition to the survivorship issues affecting the general pediatric oncology population, brain tumor survivors are at significant risk for endocrinopathies, neurocognitive dysfunction, neurological or neurosensory dysfunction, peripheral neuropathy, hearing and vision problems, seizures, stroke, headaches, secondary malignancies, and psychosocial complications. Table 3 provides a summary of the most common potential late effects, risk factors, and recommended health screening for pediatric central nervous system tumor survivors. 28 
Late Effects: Endocrinopathies
More than 40% of pediatric patients treated for central nervous system tumors develop endocrinopathies, which can be attributed to the disruption of the hypothalamic/pituitary axis due to tumor or radiation. 29 A retrospective study in an established cohort of childhood cancer survivors with 748 participants treated with cranial radiation observed for a mean of 27.3 years revealed that the estimated point prevalences was 46.5% for growth hormone deficiency, 10.8% for lutenizing hormone/follicle-stimulating hormone deficiency, 7.5% for thyroid stimulating hormone deficiency and 4% for adrenocorticotropic hormone deficiency and the cumulative incidence increased with follow-up. 30 Growth hormone deficiency is common among pediatric brain tumor survivors, occurring in nearly 100% of patients who receive a radiation dose of 36 Gy or more to the pituitary region, and is less common with radiation doses of 18-24 Gy, but may not become evident until 10 years after treatment. 31, 32 Concern has been raised about growth hormone deficiency replacement therapy having a causal role in recurrence or second malignancies. A report from the Childhood Cancer Survivor Study that evaluated the association between growth hormone replacement therapy and the development of secondary central nervous system malignancy concluded that there was no statistically significant increased overall risk of the occurrence of a secondary central nervous system malignancy associated with growth hormone replacement therapy. Specifically, occurrence of meningiomas and gliomas were not associated with growth hormone replacement therapy. 33 Neuroendocrine consequence in brain tumor survivors is complex and is best managed by an endocrinologist who works in joint collaboration with the treating oncologist.
Late Effects: Neurological
Neurocognitive dysfunction in brain tumor survivors can vary from mild to devastating. Cranial irradiation has been associated with the highest risk of long-term cognitive morbidity particularly in younger children and those receiving a higher dose. 34 Neurocognitive morbidity in attention, executive functioning, processing speed, working memory, and memory are most apparent and contribute to declines in intellectual and academic abilities. 35 Over time, skills fail to emerge at key developmental stages; thus greater time since treatment is also associated with poorer neuropsychological outcomes. 36 In a large unselected sample of long-term survivors of brain tumors, the incidence of severe neurocognitive impairment was 5% and the overall mean IQ for the sample was significantly below the normative mean. 34 Given the high rate of neurocognitive dysfunction, all survivors should be referred for neuropsychological evaluation. Early educational, cognitive, and pharmacological interventions are needed to maximize potential for recovery. 35 A childhood cancer survivor study evaluating the long-term neurologic and neurosensory sequelae in 1607 adult survivors of a primary central nervous system tumor diagnosed between 1970 and 1986, found survivors were at significant risk for hearing impairment, legal blindness, cataracts, double vision, and seizure disorder compared to a sibling cohort. Neurosensory impairment was reported in 17% of patients. Radiation exposure greater then 50 cGy to the posterior fossa was associated with a higher likelihood developing any hearing impairment. Coordination problems were reported in 49%, and motor control problems in 26%. Radiation exposure of a minimum 50 cGy to the frontal brain region had a moderately elevated risk for motor problems. Seizure disorders were reported in 25% of brain tumor survivors, including 6.5% who had a first occurrence of seizure greater than 5 years off treatment. Radiation dose of 30 cGy or more was associated with a 2-fold elevated risk for a late seizure. 37 Treatment of these problems is challenging and complex. Referral to a neuroophthalmologist for prism eyeglasses, audiologist for hearing aid and epileptologist for seizure management may be needed.
Cranial irradiation increases the risk of stroke or transient ischemic attack in pediatric brain tumor survivors. The incidence of neurovascular events in this population is 100-fold higher than in the general pediatric population. Cranial irradiation induced late vasculopathy is an important risk factor. Median time from first radiation to first event was 4.9 years. 38 Providers need to focus on primary stroke prevention.
Off-therapy headaches are also common in brain tumor patients. A retrospective review of off-therapy headaches in 81 brain tumor patients over 2 years showed that almost half of the patients with prediagnosis headaches had recurrent offtherapy headaches. A thorough medical history and neurological exam to determine the cause of the headache is critical as a headache may be a sign of tumor recurrence or second central nervous system malignancy. If the exam is significant for papilledema, hypertension or any abnormal neurological finding, diagnostic imaging with a MRI of the brain is indicated. If there is no tumor recurrence, then focus can be on determining the underlying trigger and treating symptoms. Prophylactic medication may be warranted to reduce headache frequency. 39 
Late Effects: Secondary Tumors
Development of a secondary benign or malignant central nervous system tumor is an infrequent but extremely serious late effect. A report from the Childhood Cancer Survivor Study showed that exposure to radiation therapy is the most important risk factor for the development of a new central nervous system tumor in survivors. The majority of secondary malignancies are either gliomas that tend to occur at a mean of 9 years post-initial diagnosis or meningiomas that tend to occur at a mean of 17 years postdiagnosis. The higher risk of subsequent glioma in children irradiated at a very young age may reflect greater susceptibility of the developing brain to radiation. 40 Other secondary malignancy includes sarcomas, nonmelanoma skin cancers, and thyroid cancer. 41 The majority of secondary malignancies occur in or near the radiation field. In addition to neurological examinations to detect early signs of a new or tumor recurrence, patients should be referred for routine surveillance dermatological examinations. 28 
Late Effects: Psychosocial
Children with brain tumors and those who experience insults to their central nervous system as a result of cancer or cancer treatment are at considerably high risk for adverse psychosocial outcomes. 42, 43 Survivors who have had brain or central nervous system tumors or who have had intensive central nervous system therapy appear to be most at risk for cognitive, social, and adjustment difficulties. Studies have noted that the social skills of brain tumor patients tend to be adversely affected by treatment and that patients with cognitive impairments tend to feel and be perceived as more isolated than peers 44 and to have more behavioral problems to a degree that is much higher than that of other pediatric cancer survivors. 45 A recent publication studied the long-term impact of childhood central nervous system tumors and their treatment on the self perception of adult survivors. The cohort included 697 Swedish survivors diagnosed with a primary central nervous system tumor from 1982 to 2001. The study concluded that the experience of having a central nervous system tumor combined with late effects from treatment could negatively alter self perception and self esteem, vital for mental health and quality of survival. Therefore, care and psychosocial follow-up of survivors should include measures for identifying disturbances and for assessing the need for psychosocial intervention. 46 
Long-Term Follow-Up Guidelines
The Institute of Medicine and National Research Council recommend in their report titled From Cancer Patient to Cancer Survivor: Lost in Transition that a summary of treatment and a comprehensive plan for follow-up is given to the patient and primary care provider upon completion of treatment. Such a survivorship plan will identify potential late effects and provide guidance on follow-up care, prevention, and health maintenance. 47 The Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers 28 were developed as a resource for health care professionals who provide ongoing care to survivors of pediatric malignancies. They are appropriate for asymptomatic survivors of childhood, adolescent, and young adult cancers presenting for routine risk-based medical follow-up. More extensive evaluations are performed, as clinically indicated, for survivors presenting with signs and symptoms suggesting illness or organ dysfunction. Health care professionals who do not regularly care for survivors of pediatric malignancies are encouraged to consult with a pediatric oncology long-term follow-up center if any questions arise when reviewing or using these guidelines.
Lifelong medical surveillance with a multidisciplinary team approach is essential to maximize health and improve quality of life. 26 Some pediatric cancer centers have a dedicated survivorship clinic that provides comprehensive care, education and counseling to survivors once the treatment phase is over. However, the majority of brain tumor survivors may not have access to a specialized survivorship clinic. Primary health care providers and subspecialists need to be knowledgeable of potential late effects and appropriate screening for early identification and intervention.
End-of-Life Care
DG is a 7-year-old boy with recurrent brain and spine ependymoma, first diagnosed 5 years ago. Since diagnosis he has undergone multiple brain and spine tumor resections, focal proton radiation and palliative reirradiation, and has received over 5 different chemotherapy regimens, including investigational agents. He maintained a good quality of life during treatment, attending school and engaging with family and friends in various activities outside the home. In the past 2 weeks DG has become less interactive, only occasionally opening his eyes to look at a book while his mother reads. At times he becomes agitated. He is not tolerating his oral medications, including steroids and seizure medications. He has severe dysarthria and tetraplegia. His parents agreed that quality of life has rapidly diminished, and agreed to discontinue palliative chemotherapy and transition to hospice care. His parent's main concerns at this time are the inability to communicate with DG, his periods of irritability, and the complete reliance he has on them for all personal needs.
Cancer is the leading cause of death from disease in children. While cure rates for pediatric central nervous system tumors continue to improve overall, the overall mortality rate is greater than 25% (see Figure 4 ), 48 and certain subtypes of central nervous system tumors have dismal survival rates. Diffuse intrinsic pontine glioma has a median survival rate of less than 1 year after diagnosis. The 5-year survival rate for glioblastoma multiforme is 5-15%, and is 20-40% for anaplastic astrocytoma. 49 These statistics highlight the importance of providing active end-of-life care for children with central nervous system tumors.
Common Symptoms
In the general pediatric cancer population the most commonly reported symptoms causing distress at end of life are fatigue, pain, and dyspnea. 50 In addition to these symptoms, children with central nervous system tumors have unique end-of-life care needs specific to the brain tumor population, including dysphagia and dysarthria, hearing and vision loss, paralysis, seizures, agitation, headache, and cognitive and behavioral changes. [51] [52] [53] [54] There are limited studies examining the end-oflife care needs specific to children with central nervous system tumors. More detailed adult studies exist, which highlight the unique end-of-life needs of adults with central nervous system tumors, [55] [56] [57] [58] and the data parallel the limited information available in children with central nervous system tumors. The details of these studies from children and adults are summarized in Table 4 .
One retrospective chart review of 39 children who died from central nervous system tumors at a single center found that 69% had cranial nerve deficits at end of life, 41% needed lengthy bed rest due to paraplegia, tetraplegia, or deterioration of consciousness and psychocognitive skills, and 41% had seizures. Steroids were administered in 83% of these patients, and all had at least 1 steroid side effect (e.g., cushingoid, weight gain, irritability). No patient had uncontrolled pain, though 51% received morphine, and 58% received palliative sedation, for agitation, seizures, dysphagia, and dyspnea. 53 Another study of children with cancer determined that children with central nervous system tumors had speech problems (76%), increased oral secretions (69%), headache (64%), swallowing difficulties (62%), hearing/vision problems (62%), and seizures (39%). 54 In 1 adult study the most frequent symptoms observed in the last 4 weeks of life for 169 patients (majority had glioblastoma mutliforme) were epilepsy (30%), headaches (36%), drowsiness (85%), dysphagia (85%), and agitation and delirium (15%). 55 A retrospective review of 39 adult patients with primary malignant glioma reported that end-of-life patients had poor mobility (77%), limited communication (64%), hemiparesis (62%), headaches (62%), seizures (56%), confusion (51%), and dysphagia (10%). 56 Another review of 55 adult patients with central nervous system tumors, the majority with glioblastoma multiforme, documented patients to have drowsiness/progressive loss of consciousness (87%), dysphagia (71%), progressive focal neurologic deficits (motor deficits, coordination loss, aphasia) (51%), seizures (45%), headache (33%), progressive cognitive deficits (memory loss, personality changes, apathy, problems in executive functioning and understanding) (33%), and confusion/agitation (29%). 57 And in a retrospective review of 168 patients at end of life, with central nervous system tumors of all types, patients were found to have gait impairment (65%), cognitive/personality change (62%), motor deficit (58%), seizures (57%), aphasia (27%), delirium (27%), headache (26%), and dysphagia (14%). 58 In each of these studies the authors concluded that adults with malignant brain tumors have specific symptoms during the end-of-life phase, which differ from terminally ill patients dying of other cancers.
The progressive physical impairments in children with central nervous system tumors cause a negative impact on mood, behavior and cognition. Inappropriate and impulsive behaviors can be difficult to control, and the lack of ability to communicate is frustrating, and often a significant turning point for parent and child. The unique challenges for children with central nervous system tumors at end of life lead to a palliative experience more similar to those with progressive degenerative neurologic conditions. 59, 60 Providers for children with central nervous system tumors need to learn how to manage these unique symptoms, to provide the best comfort and support for both the patient and families.
Dysphagia
The high frequency of dysphagia, as high as 62-85%, in patients with central nervous system tumors at end of life emphasizes the need for creative methods to administer medications. This is especially important for antiepileptic drugs, antiemetics, opioids, steroids, and anxiolytics, all commonly used at end of life in patients with central nervous system tumors. Pharmacists often may be able to compound medications into dosage forms that are not commercially available, for nasal, sublingual, or rectal use. For sublingual administration the liquid volume should be kept to 1-2 ml. Immediate release tablets can be crushed and mixed with water, to ease administration. Allow 5-10 minutes between sublingual doses or before eating and drinking, to promote absorption. 61 Drugs administered into the upper part of the rectum will be absorbed by the superior rectal vein, which empties into the portal vein and subsequently the liver, allowing rapid hepatic metabolism and making less drug available to the systemic circulation. 62 In adults drug volumes of 10-25 ml are easily retained, and the volume should be less than 60-80 ml to decrease chances of spontaneous expulsion. The rectal area is an alkaline environment, and alkaline preparations such as aqueous and alcohol solutions will be better absorbed than suppositories or suspensions. Inserting tablets rectally is an option, and may be an easier route than a liquid. If using tablets use immediate release, and if the rectum is dry insert 10 ml of warm water to promote dissolution. Multiple tablets can be enclosed in a gelatin capsule, either crushed or whole, to eliminate the need for multiple insertions. Entericcoated tablets should not be inserted rectally, as they require an acidic environment to dissolve. Alcoholic (elixirs) or parenteral formulations repeatedly administered sublingually or rectally can be irritating to the oral or rectal mucosa. 61, 62 Transdermal medications have not been proven to be effective beyond providing local pain relief. 61, 63 While observational studies have found some benefit to topical medications, research studies show there is inconsistent drug absorption and bioavailability; relief may be due instead to other factors, such as the soothing therapy of touch when a topical is being applied. 61 Continued research is needed to engineer effective formulations of transdermal medication. In addition, providers should not forget about the benefits of nonpharmaceutical care, such as talk therapy, massage, acupressure or aromatherapy.
Communication
Impaired communication is a significant source of distress in children and families at end of life, occurring in 27-76% of patients with central nervous system tumors, and can be due to dysarthria, aphasia, or hearing deficits. 59, 60 However there are no studies examining the communication needs of children with central nervous system tumors at end of life. Augmentative and alternative communication devices can be cost prohibitive, and a child at end of life may not have the time required to be fitted for and taught to use the device. 64, 65 More simple means of communication include writing on a dry erase board, using an alphabet or picture boards, and communication applications on computers and touch devices. 64 While these devices have limitations based on the patient's neurologic deficits, at the very end of life these devices may be useful on a very basic level to indicate wants and desires. More studies need to be performed examining the benefit of these techniques in children with central nervous system tumors and communication impairment at end of life.
Agitation and Mood
Agitation, mood fluctuations, and impulsive and inappropriate behaviors also cause significant distress for patient and caregivers at end of life. 51, 60 A change in behavior has been noted in the majority of children with central nervous system tumors at end of life, much more often than in children with hematologic or other solid tumors. 51 Benzodiazepines usage has been reported in almost 60% of children with a central nervous system tumor at end of life, to alleviate anxiety or to induce sedation for terminal dyspnea or agitation. 53 Agitation is a documented issue for adults with central nervous system tumors, occurring in 15-51% of these patients at end of life. Providers should be prepared to deal with agitation and mood and behavior changes in their pediatric patients at end of life. Symptom management may be achieved with nonpharmacological techniques, such as addressing causes of discomfort, soothing children with gentle touch and calming voices, use of familiar objects to provide comfort, and providing frequent reminders of orientation, such as clocks, calendar, or bulletin boards. Agitation may continue in spite of these measures. A review of medications may identify a possible source of agitation, confusion, or behavior changes. Medications changes must be balanced with managing other symptoms, such as headache or seizures. 66 In cases where the aforementioned actions do not help, or cannot be utilized, benzodiazepines, neuroleptics, and opioids can be given in doses to improve mood and agitation. Palliative sedation may be an acceptable outcome to manage symptoms, and should be discussed with the family. 55, 66 Headaches Headache occurs in up to 64% of children with central nervous system tumors at end of life, 55 and in 26-62% of adults with central nervous system tumors at end of life. Headache pain is often controlled by steroids, but may require additional pain relief from nonopioid or opioid pain relievers, 55 particularly if steroids are contributing to agitation.
Seizures
Seizures are a frequent symptom in patients with brain tumors, with a reported incidence of 30-57% at end of life. They may develop during the end-of-life period, or the incidence and severity can increase. Dysphagia, altered consciousness, and agitation may prohibit treatment with oral medications. Uncontrolled seizures will negatively influence quality of life, cause distress to caregivers, and can further contribute to neurologic deficits and cognitive or behavioral problems. 66, 67 Furthermore, uncontrolled seizures may necessitate hospital admission, when a patient or their family may wish for death at home. Providers can consider modifying antiepileptic drug regimens in advance, or having a plan in place in the event the patient can no longer tolerate oral antiepileptic drugs. Intramuscular, subcutaneous, sublingual, nasal, or rectal preparations should be considered. Rectal medications have the benefit of simple education and ease of use. Providers should be aware that rectal absorption of antiepileptic drugs can vary between individuals, for some drugs the bioavailability is lower rectally and the dose may need to be increased. Rectal administration never leads to higher absorption rates, and doses should not be decreased when switching from oral to rectal preparation. 68 Most liquid antiepileptic drugs can be given rectally, but consideration of the formulation being used is important. It is helpful to have a clinical pharmacist to help decide on the best preparation and any changes in dosing. 66 Diazepam and lorazepam may also be given rectally, and lorazepam is absorbed nasally, though there is limited data available. Midazolam is available nasally and buccally. 68 In any decision regarding antiepileptic drug use the side effects should be considered and discussed with the family, as some medications can cause agitation or mood changes, sedation, or further weight gain. [66] [67] [68] There is no proven benefit to prophylactic antiepileptic drugs, even in end-of-life care, and discontinuing prophylactic seizure medications is appropriate to prevent unnecessary side effects and to ease patient care. 68 Finally, if a patient continues to have breakthrough seizures despite antiepileptic drugs, or who newly develops seizures during end of life, consideration of the risks and benefits of withdrawing treatment can also be discussed. In some cases repeated focal seizures with minimal residual effects on the patient may be preferred to the complications that can arise from antiepileptic drugs. 66 
Autopsy
Autopsy should be considered in all children with central nervous system tumors at end of life. Even in the case where a gross total resection may be obtained at diagnosis, multiple tumor recurrences can occur, not all will be resected or biopsied, and at the end of life the most resistant tumors that have led to death may have never been biopsied or resected. Autopsy samples can provide information about the most aggressive component of a tumor, allow for larger specimens to be collected or for examination of multiple sites of disease, and can reveal mechanisms of tumor progression and information on the genetics of a tumor. Autopsy is especially helpful in cases where tumors are not often biopsied or resected, such as diffuse intrinsic pontine glioma.
Autopsy may provide an opportunity for a positive feeling from the death of a child, the knowledge that their death may advance research into curative therapy. Studies of have shown that the majority of families of a child with a central nervous system tumor would prefer to be offered an autopsy, and that none who consented to autopsy regretted the decision. The best time to initiate the discussion of autopsy is when the conversation has turned from curative to palliative treatment. The least desirable time is immediately before or after death. In most cases families prefer that the primary provider initiate the discussion.
Physicians may be afraid they will cause distress to the family, and may be uncertain of autopsy protocols and procedures, or uncertain of how tumor can be used for further research. Providers for children with central nervous system tumors should discuss with funeral directors, social workers and therapists, hospital pathologists, and researchers how to coordinate autopsy and tumor donation, how the sample can be used for research, and the best time and manner in which to approach the family. With a plan in place prior to discussion the family will appreciate the advanced knowledge and be able to make an informed decision. 69, 70 Discussion For children with central nervous system tumors the complexity of care throughout treatment and survivorship, or at end of life, requires a strong multidisciplinary team knowledgeable in the care of this unique population and their families throughout the spectrum of illness.
Treatment requires a multimodal approach including surgery, radiation therapy, chemotherapy, and investigational agents. Innovative methods of diagnosis, treatment, and supportive care must continue to be developed, with the goal of reducing toxicity and long-term sequelae. Beyond treatment for the tumor it is important to maximize quality of life for the patient and family's general well being. Referrals for psychosocial care, rehabilitation, and specialists in neuro-ophthalmology, endocrinology, and neuropsychiatry are as essential as primary treatment for the tumor.
Following completion of treatment, survivorship care requires more than monitoring for tumor recurrence. While advancements in treatment have resulted in improved survival rates childhood brain tumor survivors are at significant risk for adverse late effects, which can occur months to years following completion of treatment, often requiring management for the patient's lifetime. Extensive survivorship studies summarize the known late effects unique to childhood brain tumor survivors, such as neurocognitive dysfunction, psychosocial dysfunction, endocrinopathies, persistent neurologic sequelae including focal deficits, seizures, headache and stroke, and secondary malignancy. Lifelong medical surveillance for early identification of and intervention for late effects can improve overall quality of life and maximize health. An ongoing goal must be to provide adequate resources to allow these patients to reach their fullest potential.
Despite advances in treatment and improved survival rates, greater than 25% of children with central nervous system tumors will succumb to their disease. Children dying from central nervous system tumors have unique end-of-life symptoms such as impaired communication, dysphagia impairing medication administration, paralysis, headaches, seizures, and cognitive and behavioral changes, all of which add to the distress of the patient and the family. More research is needed to better understand and identify the unique aspects of care for child dying of a brain tumor.
The neurologic deficits experienced by the pediatric central nervous system tumor population are chronic or evolving issues that can impair function and quality of life and require referrals to specialists, and long-term management. With proper intervention and further research, pediatric patients with central nervous system tumors can have improved quality of life during treatment, during survivorship, or at end of life.
